Methotrexate Sodium Injection shortage
Methotrexate Sodium Injection is currently listed in shortage by the FDA. The FDA lists 14 affected products. The reported reason: Other; Demand increase for the drug. This page was last refreshed from FDA data on Oct 4, 2026.
Methotrexate sodium injection has been in shortage for over a year, driven by rising demand. Some strengths remain available from several manufacturers, and no strengths are currently listed without any supply source.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Methotrexate Sodium Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Oct 1, 2026Currently in shortage14 of 14 products affected.
-
Sep 22, 2026FDA refreshed this shortage record5 products updated.
-
Sep 18, 2026FDA refreshed this shortage record2 products updated.
-
Sep 15, 2026FDA refreshed this shortage record4 products updated.
-
Mar 13, 2023First reported to the FDA14 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Accord Healthcare Inc. 📞 866-941-7875, option 2 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) | — | Unavailable | Short dated inventory with expiry of 8/31/2027 available; Estimated recovery: TBD | Other |
| Current | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) | — | Unavailable | Estimated recovery: late September 2026; Short dated inventory with expiry of 09/30/27 available | Other |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) | — | Available | Check wholesaler for inventory | — |
| Current | Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) | — | Available | Check wholesaler for inventory | — |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) | — | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug |
| Current | Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) | — | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 5 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) | — | Available | — | — |
| Current | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) | — | Available | — | — |
| Current | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) | — | Available | — | — |
| Current | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) | — | Available | — | — |
| Current | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) | — | Available | — | — |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) | — | Limited Availability | Estimated recovery: October 2026 | Other |
| Current | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) | — | Limited Availability | Estimated Recovery: Novemeber 2026 | Other |
| Current | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) | — | Limited Availability | Estimated recovery: October 2026 | Other |
These rows are manufacturer reports to the FDA for Methotrexate Sodium Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Methotrexate Sodium Injection? options further down this page.
Why is Methotrexate Sodium Injection in shortage?
There are two things driving the shortage of injectable methotrexate sodium right now: more people needing this medication than usual, and some unspecified manufacturing or supply issues that the companies reported simply as "other" without sharing more detail publicly. For Hikma specifically, higher demand is the main culprit — they expect new batches of the 1 g vials around September 2026 and the 25 mg/1 mL vials around October 2026. Accord's 25 mg/1 mL vials are currently unavailable too — one package size has an estimated recovery of late September 2026, while the other has no firm recovery date yet, though some short-dated inventory (expiring 8/31/2027 and 9/30/2027) is available. Teva's 25 mg/1 mL vials are in limited supply, with recoveries estimated between October and November 2026.
It's worth knowing that this report covers only the manufacturers who filed it. Some versions of this drug — including certain products from Fresenius Kabi and Hospira/Pfizer — are reported as currently available through this same FDA report.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Methotrexate Sodium Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Methotrexate Sodium Injection?
Methotrexate Sodium Injection is currently on the FDA shortage list. If you use this medicine, the first thing to know is that every strength still has at least one supplier, so this is a manageable situation rather than an emergency.
All five listed strengths — 25 mg/1 mL, 1 g, 50 mg/2 mL (25 mg/mL), and 1 g/40 mL (25 mg/mL) — still have an available source. No strength is completely without supply right now. Some manufacturers report their lots as unavailable or limited, while others (including Fresenius Kabi and Hospira) report their products as available.
The reasons given are higher demand for the drug and "other" supply factors. Three of the five manufacturers on this record are still reporting supply, and several expect more lots in the September through November 2026 timeframe. This shortage has lasted over a year, but the overall supply risk is rated low.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength; they can check wholesalers and other manufacturers.
- The same medicine is made by several companies on this list, so your pharmacy may be able to source one, though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Methotrexate Sodium Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Methotrexate Sodium Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Methotrexate | METHOTREXATE 1 g/1 | Injection, Powder, Lyophilized, For Solution · Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9367-01 |
| Methotrexate | METHOTREXATE SODIUM 25 mg/mL | Injection, Solution · Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Teva Parenteral Medicines, Inc. | 00703-3678-81 |
| Methotrexate | METHOTREXATE 25 mg/mL | Injection · Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Accord Healthcare, Inc. | 16729-0277-03 |
| Methotrexate | METHOTREXATE SODIUM 25 mg/mL | Injection, Solution · Intramuscular, Intrathecal, Intravenous, Subcutaneous | Hospira, Inc. | 61703-0161-05 |
Alternative dosage forms of Methotrexate Sodium
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 11 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Methotrexate 25 mg/mL | Hikma | 10 vials | $1.237 | AP | Availability likely |
| Methotrexate 25 mg/mL | Accord | 1 vial | $1.803 | AP | Availability likely |
| Methotrexate 25 mg/mL | Hospira, | 5 vials | $3.183 | AP | Availability likely |
| Methotrexate 25 mg/mL | Hospira, | 5 vials | $3.183 | AP | Availability likely |
| Methotrexate 25 mg/mL | Fresenius | 1 vial | $3.183 | AP | Availability likely |
| Methotrexate 25 mg/mL | Hikma | 1 vial | — | AP | FDA listed |
| Methotrexate 25 mg/mL | Hikma | 1 vial | — | AP | FDA listed |
| Methotrexate 25 mg/mL | Hikma | 1 vial | — | AP | FDA listed |
| Methotrexate 25 mg/mL | Accord | 1 vial | — | AP | FDA listed |
| Methotrexate 25 mg/mL | Alembic | 5 vials | — | AP | FDA listed |
| Methotrexate 25 mg/mL | Alembic | 5 vials | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Methotrexate Sodium Injection — that fall in the same broad treatment class (antineoplastic - antimetabolites) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Methotrexate Sodium Injection shortage FAQs
Is Methotrexate Sodium Injection in shortage?
Why is Methotrexate Sodium Injection in shortage?
Which products are affected?
When will Methotrexate Sodium Injection be available again?
Can I still get Methotrexate Sodium somewhere?
What should I do if I take Methotrexate Sodium Injection?
Still have a question about the Methotrexate Sodium Injection shortage?
Ask a pharmacist about this shortage →View Methotrexate Sodium Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.